ABSTRACT

N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS

(l)

$$\begin{array}{c|c} R_3 & W \\ \hline R_4 & & \\ \hline R_5 & & \\ \hline R_8 & & \\ \hline R_7 & \\ \hline R_2 & \\ \end{array}$$

Described are compunds of formula (I), wherein W is O or S; X is NR₈; Y is CR₉R₁₀-(CH₂)n wherein R₉ and R₁₀ are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO₂; R₁ is aryl; R₂ is a monoor bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R₂ cannot represent 2-phthalimidyl, and in case of Y = SO₂ cannot represent 2,1,3-benzothiadiazol-4-yl; any of R₃, R₄, R₅ and R₆, independently of the other, is H or a substituent other than hydrogen; and R₇ and R₈, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.